Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer

Hailiang Ran(Kunming Medical University), Yuanyuan Xiao(Jinan University), Yunchao Huang(Kunming Medical University), Le Cai(Kunming Medical University), Jie Ma(Kunming Medical University), Ying Chen(Shandong University of Traditional Chinese Medicine), Hai Zhou(Yuncheng University), Zhongqin Yuan(Kunming Medical University), Wei Chang(Kunming Medical University)
BMC Cancer
January 21, 2022
10.1186/s12885-022-09212-0
Cited by 25

Related Papers

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Cancer|2021|106
Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C)
|The American Journal of Gastroenterology|2020|78
Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy
|EBioMedicine|2017|77
miR‐152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines
|The Prostate|2013|76